Literature DB >> 17339864

Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.

K S Patrick1, A B Straughn, R R Minhinnett, S D Yeatts, A E Herrin, C L DeVane, R Malcolm, G C Janis, J S Markowitz.   

Abstract

This study explores the hypotheses that: (1) ethanol will interact with dl-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dl-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women. Pharmacokinetic parameters were compared. Subjective effects were recorded using visual analog scales. One subject was a novel poor MPH metabolizer whose data were analyzed separately. Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2). l-MPH was present in plasma only at 1-3% of the concentration of d-MPH, except in the poor metabolizer where l-MPH exceeded that of d-MPH. The metabolite l-ethylphenidate frequently exceeded 1 ng/ml in plasma, whereas d-ethylphenidate was detected only in low pg/ml concentrations. Women reported a significantly greater stimulant effect than men when questioned "Do you feel any drug effect?" (P<0.05), in spite of lower mean plasma d-MPH area under the response-time curves in women. Ethanol elevates plasma d-MPH C(max) and area under the concentration-time curve by approximately 40% and 25%, respectively. If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy. The more pronounced stimulant effects experienced by women have sex-based abuse liability implications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339864      PMCID: PMC3188424          DOI: 10.1038/sj.clpt.6100082

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.

Authors:  M C Meyer; A B Straughn; E J Jarvi; K S Patrick; F R Pelsor; R L Williams; R Patnaik; M L Chen; V P Shah
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  Oral methylphenidate-alcohol co-abuse.

Authors:  Sean P Barrett; Robert O Pihl
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

3.  Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol.

Authors:  J S Markowitz; C L DeVane; D W Boulton; Z Nahas; S C Risch; F Diamond; K S Patrick
Journal:  Drug Metab Dispos       Date:  2000-06       Impact factor: 3.922

Review 4.  New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Kennerly S Patrick; Mario A González; Arthur B Straughn; John S Markowitz
Journal:  Expert Opin Drug Deliv       Date:  2005-01       Impact factor: 6.648

5.  Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder.

Authors:  J Biederman; T Spencer
Journal:  J Atten Disord       Date:  2002       Impact factor: 3.256

6.  The brief MAST: a shortened version of the Michigan Alcoholism Screening Test.

Authors:  A D Pokorny; B A Miller; H B Kaplan
Journal:  Am J Psychiatry       Date:  1972-09       Impact factor: 18.112

Review 7.  Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.

Authors:  John S Markowitz; Arthur B Straughn; Kennerly S Patrick
Journal:  Pharmacotherapy       Date:  2003-10       Impact factor: 4.705

Review 8.  Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.

Authors:  Nora D Volkow; James M Swanson
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

9.  Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.

Authors:  S H Heil; H W Holmes; W K Bickel; S T Higgins; G J Badger; H F Laws; D E Faries
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

10.  Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors.

Authors:  Christian J Teter; Sean Esteban McCabe; Carol J Boyd; Sally K Guthrie
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

View more
  58 in total

Review 1.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

3.  Extended release stimulant medication misuse with alcohol co-administration.

Authors:  Jessica R Meisner; Christine Darredeau; Megan E McLarnon; Sean P Barrett
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-11

Review 4.  The role of human carboxylesterases in drug metabolism: have we overlooked their importance?

Authors:  S Casey Laizure; Vanessa Herring; Zheyi Hu; Kevin Witbrodt; Robert B Parker
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

5.  Effects of methylphenidate on the aggressive behavior, serotonin and dopamine levels, and dopamine-related gene transcription in brain of male Nile tilapia (Oreochromis niloticus).

Authors:  Isabela Gertrudes Batalhão; Daína Lima; Ana Paula Montedor Russi; Camila Nomura Pereira Boscolo; Danilo Grunig Humberto Silva; Thiago Scremin Boscolo Pereira; Afonso Celso Dias Bainy; Eduardo Alves de Almeida
Journal:  Fish Physiol Biochem       Date:  2019-05-03       Impact factor: 2.794

6.  Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.

Authors:  S Casey Laizure; Robert B Parker; Vanessa L Herring; Zhe-Yi Hu
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

7.  Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.

Authors:  E Katriina Tarkiainen; Aleksi Tornio; Mikko T Holmberg; Terhi Launiainen; Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

Review 8.  Attention-deficit/hyperactivity disorder genomics: update for clinicians.

Authors:  Josephine Elia; Jillan Sackett; Terri Turner; Martin Schardt; Shih-Ching Tang; Nicole Kurtz; Maura Dunfey; Nadia A McFarlane; Aita Susi; David Danish; Alice Li; Jenelle Nissley-Tsiopinis; Karin Borgmann-Winter
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

9.  Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation.

Authors:  Hao-Jie Zhu; John S Markowitz
Journal:  Eur J Clin Pharmacol       Date:  2012-07-31       Impact factor: 2.953

10.  Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.

Authors:  Natalie L LeVasseur; Hao-Jie Zhu; John S Markowitz; C Lindsay DeVane; Kennerly S Patrick
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-12-04       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.